Simpson Ian D
WHO Snakebite Treatment Group, Nayathode.
J Indian Med Assoc. 2007 Jun;105(6):324, 326, 328 passim.
Snakebite in India continues to be a matter of medical concern and India remains amongst the group of countries with the highest mortality. India is also one of the world's leading producers of snake venom antiserum and therefore the understanding of the causals of snakebite mortality does not rest in snake venom antiserum shortages. The availability of treatment, particularly close to the scene of the bite, is a crucial factor in ensuring a positive outcome. In the majority of the States in India, 90+% of medical facilities are primary healthcare centres run by one doctor and with only basic equipment. If snakebite treatment is to be successful, these centres are a vital element, but virtually all existing treatment guides assume treatment at tertiary care hospitals with better equipment. A great many of these primary care hospitals do not treat snakebite, even when snake venom antiserum is available, simply because the doctor lacks confidence in being able to treat the patient. The result is that patients are referred to distant, better equipped hospitals and thus make journeys without the cover of snake venom antiserum. This paper provides guidance for the primary healthcare doctor in identification of medically significant snakes, treatment, referral criteria and equipment necessary to successfully manage snakebite in a primary care environment.
在印度,蛇咬伤仍然是一个医学关注的问题,印度仍是死亡率最高的国家之一。印度也是世界上主要的蛇毒抗血清生产国之一,因此,蛇咬伤死亡率的原因并不在于蛇毒抗血清短缺。治疗的可及性,尤其是在咬伤现场附近的可及性,是确保取得良好治疗效果的关键因素。在印度的大多数邦,90%以上的医疗设施是由一名医生运营且只有基本设备的基层医疗中心。如果蛇咬伤治疗要取得成功,这些中心是至关重要的因素,但几乎所有现有的治疗指南都假定在设备更好的三级医院进行治疗。即使有蛇毒抗血清,许多这类基层医疗医院也不治疗蛇咬伤,仅仅是因为医生缺乏治疗患者的信心。结果是患者被转诊到遥远的、设备更好的医院,从而在没有蛇毒抗血清保障的情况下辗转就医。本文为基层医疗医生在基层医疗环境中识别具有医学重要性的蛇类、进行治疗、确定转诊标准以及成功处理蛇咬伤所需的设备等方面提供指导。